Combining
Herceptin and a tyrosine kinase inhibitors
Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 5 2000
Play
Audio Below:
I
think a real interesting question would be if you used Herceptin and combined
it with a TK inhibitor for HER2, would you get a greater bang than if
you just used Herceptin alone. We don’t have, obviously, any clinical
data and, indeed, there’s very little in the way pre-clinical data
at this point. Probably the more interesting ones though are going to
be combinations of Herceptin with tyrosine inhibitors that inactivate
the epidermal growth factor receptor. EGFR, the epidermal growth factor
receptor, preferentially dimerizes with HER2. HER2 itself doesn’t
have a ligand, but is the preferential dimerization partner with all the
other members of the epidermal growth factor receptor family. So, a one-two
punch where we shut down Herceptin externally and shut down the epidermal
growth factor receptor internally ¾ since we know that in many cases
EGFR has a truncated form where it, in fact, doesn’t have an external
domain ¾ actually it makes a good deal of sense and it’s certainly
something well worth looking at in the clinic.
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
[Review]. Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl
9):13-19, 2000 Oct.
In
process Current and planned clinical trials with trastuzumab (Herceptin)
[Review]. Baselga, J. Seminars in Oncology. 27(5 Suppl 9):27-32, 2000 Oct. In
process
Clinical
trials of single-agent trastuzumab (Herceptin) [Review]. Seminars in Oncology. 27(5 Suppl 9):20-26, 2000 Oct. In proces
Biological
rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
[Review].
Pegram, M. and Slamon, D Seminars in Oncology. 27(5 Suppl 9):13-19, 2000
Oct. In
process
The
use of HER2 testing in the management of breast cancer [Review]. Ravdin, P. Seminars in Oncology. 27(5 Suppl 9):33-42, 2000 Oct. In
process
